Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants used in Atrial Fibrillation

Ameenathul M Fawzy & Gregory YH Lip

To cite this article: Ameenathul M Fawzy & Gregory YH Lip (2019): Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants used in Atrial Fibrillation, Expert Opinion on Drug Metabolism & Toxicology, DOI: 10.1080/17425255.2019.1604686

To link to this article: https://doi.org/10.1080/17425255.2019.1604686

Accepted author version posted online: 05 Apr 2019.

Article views: 9

View Crossmark data
Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants used in Atrial Fibrillation

Ameenathul M Fawzy¹, Gregory YH Lip²,³,*

¹City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, Birmingham, United Kingdom
²Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
³Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

*Corresponding author: Gregory YH Lip, Email: gregory.lip@liverpool.ac.uk
Abstract

Introduction: The availability of non-vitamin K antagonist oral anti-coagulants alongside vitamin K antagonists has offered a variety of options for anti-coagulation, but has also necessitated a good understanding of the pharmacological properties of each of these drugs prior to their use, to maximise the therapeutic benefit and minimise patient harm.

Areas covered: This review article outlines the pharmacokinetic and pharmacodynamic profiles of the currently licensed NOACs and VKAs that are most commonly used in clinical practice, with the aim of demonstrating how variations in these processes contribute to their use in clinical practice. A literature search was conducted on PubMed using keywords and relevant articles published by the 31st of December 2018 were included.

Expert opinion: The effect of a drug is determined by a combination of elements which include patient characteristics and external influences, in addition to its pharmacokinetic and pharmacodynamic properties. A good understanding of this is essential. Despite the wealth of information available, particularly on VKAs, our knowledge on the pharmacology responsible for certain drug effects and inter-individual variations is still limited. Increasing efforts are being made to uncover these and includes focus on pharmacogenomics and drug transporter proteins.

Keywords: warfarin, vitamin K antagonists, non-vitamin K antagonists oral anticoagulants, dabigatran, rivaroxaban, apixaban, edoxaban, pharmacokinetics and pharmacodynamics, atrial fibrillation
ARTICLE HIGHLIGHTS BOX

• Understanding of physiological processes such as the coagulation cascade is important to discern how oral anticoagulant (OAC) agents bring about their effects.

• Vitamin K antagonists (VKAs) affect multiple components (vitamin K dependent clotting factors II, VII, IX, X and proteins C and S) involved in the coagulation process whereas the non-vitamin K antagonists (NOACs) are more selective in their targets.

• The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the OACs vary from each other, even when the drugs are structurally similar. They play a key role in determining the safety of the drug.

• Mechanisms of drug interactions include those which affect drug absorption, its distribution and the induction or inhibition of enzymes involved in the metabolism and elimination of the drug.

• A good comprehension of the mechanisms of drug interactions is necessary for the safe prescription of OACs.
1. Introduction
The discovery of oral anticoagulant (OAC) agents in the form of vitamin K antagonists (VKAs) was a boon to mankind and for over 60 years they occupied the limelight as the exclusive choice in the long-term the prevention and treatment of stroke associated with atrial fibrillation (AF) and other thromboembolic disorders. However, their slow onset of action, narrow therapeutic range, titrated dosing, requirement for monitoring, large inter-individual variability and multifarious interactions with other drugs and food are amongst the limitations which have been a source of numerous clinical plights, giving rise to the development of direct or non-vitamin K antagonists (DOACS/ NOACs)[1,2]. Although they have similar effects in terms of their clinical effect (i.e. anticoagulant activity), the pharmacological profile of NOACs varies to that of warfarin, accounting for their superiority in multiple domains.

Hence, a good understanding of the physiological processes as well as the pharmacokinetics (PK) [what the body does to the drug] and pharmacodynamics (PD) [what the drug does to the body]) of the drugs is necessary to appreciate the differences, so that this knowledge can be utilised in the decision-making processes regarding the choice of OAC[3,4]. Hence, this review article aims to provide a detailed review of these characteristics of the commonly used VKAs (warfarin (Coumadin®), phenprocoumon (Marcumar®) and acenocoumarol (Sinthrome®)) as well as NOACs (dabigatran (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis®) and edoxaban (Lixiana®) . A recent article in this journal by Ingrasciotta and colleagues[5] also discusses the pharmacokinetics of NOACs and its implications on routine clinical care.


1.1 The clotting cascade
The coagulation cascade comprises of proteolytic enzymes and cofactors, each which catalyse the activation of the next, giving rise to an amplification sequence of events which ultimately result in the formation of a clot or thrombus. It may be triggered by two major pathways; the intrinsic (contact) and extrinsic (tissue factor) pathways (Figure 1). Both these pathways eventually lead to the formation of prothrombin activator (also known as activated factor X) which plays an integral role in the coagulation process[6].

The extrinsic pathway is initiated with trauma to tissue or vascular injury resulting in the release of tissue factor (TF), also known as Factor III. TF catalyses the activation of factor VII
to VIIa and the tissue factor-VIIa complex then results in the activation of factor X (FX). Activated factor X (FXa) along with its co-factor activated factor V (FVa), then result in the generation of thrombin (FII) from its precursor prothrombin. Thrombin leads to the activation of soluble fibrinogen into insoluble fibrin (FI) monomers which in the presence of factor XIII, form fibrin polymers, resulting in the formation of a clot[6].

The extrinsic pathway initially results in the production of small amounts of thrombin. This thrombin activates platelets as well as factors V, VII, VIII, XI and XIII, to further amplify the process and lead to formation of more fibrin strands.

The intrinsic pathway is usually triggered where there is trauma to the blood cells or exposure of the plasma to artificial surfaces. While it is less significant to haemostasis under normal physiological conditions, it is implicated in thrombotic diseases[7]. The intrinsic pathway is initiated with the activation of factor XII to FXIIa which catalyses the formation of activated factor XI (FXIa). FXIa then acts on factor IX to activate it, so that activated factor IX (FIXa) and its activated co-factor FVIIIa can together result in the formation of FXa. Both the extrinsic and intrinsic pathways therefore converge at the point where there is activation of FX[6] (Figure 1).

FXa plays a crucial role in the coagulation processes arising from both pathways, by propagating the fundamental step which is the conversion of prothrombin to thrombin. Further, it is key in the amplification process as one molecule of FXa catalyses the formation of approximately 1000 molecules of thrombin[8], making it an attractive target to hinder the coagulation process[9]. Currently, the majority of NOACs (rivaroxaban, apixaban and edoxaban) specifically target FX, while the remaining NOAC dabigatran inhibits thrombin. All of these are target specific, unlike VKAs which affect multiple components in the cascade, as demonstrated in figure 1.

This is amongst the reasons why NOACs have a favourable safety profile (Table 3), particularly in their reduction of the risk of intracerebral haemorrhage (ICH) when compared to VKAs[10]. In particular, VKAs affect factor VII which plays a crucial part in brain haemostasis[11].

Fibrinolysis begins once the structural integrity of the vessels starts to get restored. Endothelial cells secrete tissue plasminogen activator which activates the protease plasmin to degrade fibrin. Thrombin also gives rise to plasmin from plasminogen, which acts directly on the mesh networks of fibrin to break them apart[12]. Moreover, it stimulates production of anti-thrombin through a negative feedback loop, which in turn decreases the amount of thrombin generated from prothrombin as well as the activated FXa. Another natural anti-thrombotic mechanism of the body is the protein C/S system which is also influenced by VKAs due to their vitamin K dependence[13].
2. Vitamin K antagonists

The discovery of VKAs was inadvertent, starting with the perplexing deaths of cattle which, on post-mortem were found to have extensive bleeding and bruising. The source of this was identified as sweet clover and the condition was subsequently dubbed ‘haemorrhagic sweet clover disease’. It was soon discovered that this was associated with a deficiency of prothrombin and the role of vitamin K in preventing bleeding was established.

Although first used commercially as a rodent poison, warfarin was approved for medical use in 1954 and has been in the market since[14]. Phenprocoumon and acenocoumarol, followed shortly afterwards and are used in many countries. Other vitamin K antagonists include dicoumarol, fluindione, phenindione etc which are not as extensively used[15,16] Table 1 summarises the pharmacokinetic properties of the commonly used warfarin, phenprocoumon and acenocoumarol.

2.1 Mechanism of action

The coagulation factors II, VII, IX and X require $\gamma$-carboxylation for their biological activity, with vitamin K acting as a co-factor for this process; hence why they are regarded as the vitamin K dependent clotting factors. Under normal circumstances, $\gamma$-carboxylation induces a conformational change in these coagulation proteins that promotes their binding to co-factors on phospholipid surfaces.

The carboxylation reaction also involves the simultaneous oxidation of vitamin KH$_2$ (reduced form of vitamin K) to vitamin K epoxide (Figure 2). As vitamin K is recycled, the vitamin K epoxide is reduced back to vitamin KH$_2$ via a 2-step process. It is first converted to vitamin K$_1$, the natural food form of vitamin K, and then vitamin KH$_2$. Both of these are reductase processes but only the first is sensitive to VKAs. VKAs non-competitively inhibit the vitamin K epoxide reductase complex subunit 1 (VKORC1), preventing the enzyme from catalysing the first reaction. Although VKAs interfere with the coagulation process by limiting the recycling of vitamin K, this can be counteracted by replacement of vitamin K$_1$ through oral supplementation with food or therapeutic administration due to the second step being unaffected by these drugs. Vitamin K$_1$ can accumulate in the liver and can result in warfarin resistance for up to a week, if present within the system in large amounts[17,18].

In addition to this, VKAs also inhibit the carboxylation process of the proteins C and S that are part of the body’s natural anticoagulant system, and may potentially induce a pro-coagulant effect. However, their anticoagulant effect is dominant in most circumstances[13,17].

The protective action of VKAs arises from their effect on prothrombin which is prerequisite to thrombus formation. Although an anticoagulant effect is initiated within 2 days, the full
antithrombotic effect requires a longer period of 6 days due to the long half-life of factor II (prothrombin) which is about 60 to 72 hours[19].

The concentration-effect of VKAs is variable. In a study by Penner and colleagues, treatment with warfarin for 14 days resulted in a reduction in FVII and X levels compared to the control by 30% and 20% respectively. Warfarin concentrations at this point were 1.2mg/L. In contrast, Porter et al demonstrated FX activities which were 60% of that of the control after warfarin intake for a similar period. Plasma concentrations of warfarin were 2.5mg/L[20].

2.2 Measuring VKA effects
The international normalised ratio (INR) is universally used as a standardised measure of the anticoagulant activity of VKAs. It is defined as the ratio of prothrombin time (PT) measured in a patient to that of a control, measured as per the World Health Organisation primary standard. PT is the time required for coagulation to occur in vitro and is initially reflective of the reduction in factor VII which has a short half-life of 6 hours[21]. Thereafter, factors X and prothrombin which have longer half-lives contribute to it[22].

2.3 Warfarin
Warfarin is the most widely used VKA. It is a highly water soluble compound made up of roughly equal proportions of both its R and S isomers. All VKAs exist as roughly equimolar racemic mixtures of their two, optically active R and S enantiomers, each which have different chemical properties. In a study that involved administration of single doses of both R and S warfarin to healthy volunteers, O’Reilly and colleagues demonstrated that the area under the plasma concentration time curve (AUC) was 1.9 times higher for R-warfarin than S-warfarin warfarin, indicating a lower clearance rate for the R-form. Further, they also showed that the inhibitory effect of S-warfarin on prothrombin was 1.8 times higher than R-warfarin, suggesting that the S-form is about two to five-fold more potent than the R-form. This is also true for phenprocoumon and acenocumarol[23–26].

Absorption: Warfarin is rapidly absorbed from the gastro-intestinal (GI) tract following oral administration, with the stomach and proximal GI tract being the main sites. Maximal plasma concentrations (Cmax) are achieved within 3-9 hours of oral administration[27]. Warfarin absorption is dissolution-rate controlled but there are several other factors that can influence this. Significant inter-individual variations also exist[27]. Warfarin has an essentially complete oral bioavailability[28].

Distribution: Over 99% of warfarin found in the plasma is protein-bound with virtually all of it attached to albumin[27]. Consequently, only a small amount of free drug is available to
exert its biological effects. The volume of distribution ranges from 8-12% of the total body weight and this does not differ significantly between the enantiomers[28].

**Metabolism:** The metabolism of warfarin is stereoselective and the two enantiomers undergo hepatic transformation via different pathways[29] by the hepatic cytochrome P450 (CYP450) enzymes. The CYP450 enzymes involved include CYP 2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. The more potent S-warfarin is metabolised by CYPC29 while CYP1A2 and CYP3A4 are predominantly responsible for the metabolism of R-warfarin[30]. These enzymes catalyse the hydroxylation reactions which result in the formation of inactive, hydroxylated metabolites as well as cis- and trans-dehydro-warfarins. Five different hydroxylated metabolites of warfarin have been identified. Furthermore, two diastereomeric alcohols with minimal anticoagulant activity are also formed via reduction processes which occur in the endoplasmic reticulum and cytosol[31,32]. Limited data are available on the phase II metabolism of warfarin which includes the glucuronidation and sulfation of hydroxylated metabolites. This has been mainly observed in rats in which the R-warfarin metabolites had undergone either glucuronidation, sulfation or both[33]. In humans however, these reactions appear to be insignificant.[32] CYP2C9 is the primary enzyme responsible for the metabolism of warfarin and patients with polymorphisms of these enzymes which have a reduced function require lower doses of warfarin due to their risk of over-anticoagulation[30,34,35].

**Excretion:** The elimination of warfarin is almost exclusively dependent on metabolism, with hydroxylation and reduction processes encompassing 80-85% and 15-20% of metabolic clearance respectively[29]. As a result, only miniscule amounts of unchanged drug are excreted. Approximately 80% of the metabolites are recovered in urine while the other 20% is excreted via the faecal route[36]. The half-life of R-warfarin is 45 hours and S-warfarin is 29 hours, leading to an overall half-life which ranges from 36-42 hours[22]. The effects of warfarin can last from 2-5 days[37].

**Interactions:** A myriad of interactions occur between warfarin and other drugs, as well as food, owing to a number of mechanisms (Table 4). These include agents that affect the absorption of warfarin (e.g. cholestyramine and sucralfate), its metabolism (e.g. CYP450 inhibitors or inducers such as rifampicin and phenobarbital) or displacement from the protein binding sites (e.g. quinidine) which can increase the amount of free drug available to exert anti-coagulant effects[38,39]. In addition, interactions may also depend on which of the isomers are affected as their potency and clearance differs from one another[23]. For example, phenylbutazone when co-administered with warfarin, results in effects which are stereo-selective. Like warfarin it has a high affinity for plasma proteins, leading to warfarin’s displacement from its albumin binding sites and increased plasma concentrations of active warfarin. As phenylbutazone is a selective inhibitor of CYP2C9, metabolism of the potent S-enantiomer of warfarin and therefore its clearance, is reduced[29]. Appropriate dose
adjustments or complete avoidance of an interacting drug may be necessary to avoid adverse reactions.

2.4 Phenprocoumon
Phenprocoumon is another vitamin K antagonist and coumarin derivative which like the others. It is more commonly used in European countries such as Germany. In healthy volunteers who took 12mg of phenprocoumon, there was an earlier prolongation of PT, than there was a reduction in prothrombin.[40]

**Absorption:** phenprocoumon is rapidly absorbed after oral intake and has an oral bioavailability of 100%[32].

**Distribution:** over 99% of phenprocoumon is protein bound and it has a volume of distribution between 0.11-0.14 L/kg[40].

**Metabolism:** phenprocoumon undergoes phase I metabolism by CYP29 enzymes predominantly, resulting in the formation of its 4 inactive, hydroxylated metabolites[41]. These then undergo phase II metabolism via glucuronidation[41,42]. Other enzymes implicated in the metabolic processes include CYP 2C8 and 3A4 classes which have been identified using recombinant CYP enzymes within prepared human liver microsomes[43].

**Excretion:** unlike warfarin and acenocoumarol whose elimination is almost entirely dependent on metabolism, only 60% of phenprocoumon is excreted as metabolites. The remainder is removed in an unchanged form. The majority (about 65%) is eliminated by the kidneys and the other 35% is[41] excreted via the faeces. The terminal half-life of phenprocoumon is much longer in comparison to the others. This is thought to be secondary to the lower intrinsic clearance of the enzymes involved in the hydroxylation reactions as well as the extensive entero-hepatic recycling of the conjugated phenprocoumon[32].

**Interactions:** given the involvement of the CYP C29, 3A44 and 2C8 enzymes in phenprocoumon metabolism, any drugs which can affect their function can result in adverse reactions, when given together with phenprocoumon. However, phenprocoumon is much less susceptible to interactions compared to warfarin and acenocoumarol, owing to the different pathways of metabolism and excretion. For example, cimetidine when given together with warfarin results in its increased plasma levels and prolongation of PT but these parameters were unaffected when administered with phenprocoumon[44,45]. This is explained by its effects on the enzymes CYP1A2 and CYP 2C19 which are involved in the metabolism of warfarin but play no role in that of phenprocoumon.
2.4 Acenocoumarol

Acenocoumarol also belongs to the family of VKAs and is used considerably in France and Italy. The clinical activity of acenocoumarol is mainly dependent on R-acenocoumarol despite being the less potent isoform, due to its longer half-life.[46]

**Absorption:** Acenocoumarol undergoes rapid absorption after oral intake with $C_{\text{max}}$ being achieved within 3 hours[47]. In contrast to the other VKAs, the S-enantiomer of this drug undergoes first pass metabolism, making its oral bioavailability relatively lower, though still high (96%)[15].

**Distribution:** Approximately 98% of acenocoumarol is protein-bound within the plasma[47]. Its volume of distribution ranges from 0.22-0.52 L/kg[32].

**Metabolism:** The metabolism of acenocoumarol takes place in the liver with CYP2CP playing the major role. It exclusively hydroxylates S-acenocoumarol and is also the main enzyme involved in the hydroxylation of R-acenocoumarol, which undergoes hydroxylation reactions by two other enzymes, CYP1A2 and CYP2C19[48]. Acenocoumarol also undergoes reduction to form amino and acetamido metabolites as well as alcoholic forms but the enzymes accountable for these processes are undiscovered[32,48].

**Excretion:** Similar to warfarin, nearly all of the absorbed acenocoumarol is eliminated as metabolites with <1% present in urine or faeces in its unchanged form. The proportions excreted in urine and faeces are 65% and 35% respectively[47].

**Interactions:** drugs affecting the CYP enzymes 1A2, 2C19 and particularly 2C9 can attenuate or potentiate the anticoagulant activity of acenocoumarol. When co-administered with phenylbutazone which selectively inhibits CYP2C9, the clearance of S-acenocoumarol in rats was two times lower[49]. Concurrent administration therefore requires careful consideration.
3. The Non-vitamin K antagonist oral anticoagulants

In contrast to VKAs, NOACs are specific in their mode of action, have fixed dose regimens without the need for routine monitoring, a rapid onset of action, relatively low inter-individual variability with consistency seen across age, gender and ethnicity and fewer interactions with food and drugs, making them a more convenient and attractive choice (Table 2)[50]. The four large phase III trials which have led to the licensing of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation are the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial[51], Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF)[52], Apixaban for Reduction of Stroke and Other Thromboembolic Evens in Atrial Fibrillation (ARISTOTLE)[53] and Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trials respectively[54]. These drugs have also received approval for use in the treatment and prevention of venous thromboembolism (VTE). Additionally, in light of recent evidence indicating a reduced risk of cardiovascular mortality, myocardial infarction (MI) and stroke, low-dose rivaroxaban is approved for use in patients with acute coronary syndromes.[55–57] Table 3 summarises the main safety outcomes of these drugs in the respective trials.

3.1 Measuring NOAC effects

Although the inter-and intra-subject variability in the PK of NOACs have been reported as low, notable variations in drug blood levels have been observed in phase III trials of NVAF patients[58,59]. Further, these levels have been shown to correspond with efficacy and safety outcomes. In a pre-specified PK analysis of the RE-LY trial, the risk of ischemic events inversely correlated with dabigatran trough levels (p=0.045), while the major bleeding risk increased with dabigatran exposure (p<0.0001). Significant variations were observed in plasma concentration and renal function was identified as the predominant characteristic determining this, with age, weight and female sex also acting contributing factors. The median trough levels were 55% higher in subjects who had a bleeding event, compared to those who did not[60].

Similarly, a further analysis from the ENGAGE-TIMI-AF trial also demonstrated a dose-response relationship with higher rates of ischemic and bleeding events occurring in patients who had dose reductions, although the efficacy of edoxaban compared to warfarin was reportedly preserved. These findings question the lack of need for routine monitoring of plasma concentrations, at least for a subset of patients whose clinical characteristics may influence concentrations or who may be at an increased risk of developing ischaemic/bleeding complications despite being on the indicated dose. The PK analysis of the RE-LY trial well-demonstrated the wide variation in plasma drug concentrations and the wide therapeutic range of dabigatran etexilate. Hence, determining an arbitrary cut-off level to guide dose changes can be challenging. At the same time, a dose reduction based on a
certain clinical characteristic alone, intended to reduce risks of bleeding, may occur at the expense of a much higher risk of stroke.

In a study by Testa et al.[61] attempting to determine a relationship between DOAC trough levels and thromboembolic events, these complications were observed only in patients who had very low trough levels. 40.5% of the 565 patients in the study were treated with lower doses, as per recommendations from the guidelines due to presence of renal dysfunction and other indications. The mean CHA2DS2-VASc score was notably higher in this group compared to the total patient population (5.3 vs. 3.0) but thromboembolic complications were not reported in high cardiovascular risk group that had higher anti-coagulant levels. The study’s findings also demonstrated a high inter-individual variability in drug trough levels at steady state; suggesting older age, multiple co-morbidities and increasing use of prescription drugs as possible factors contributing to this and thus the anti-coagulant effect.

The authors highlighted that the fixed dose of DOACs may therefore not be applicable to the ‘real-word patient’ whose profile may not fit that of a trial subject on whom the dose calculation would have been based on. While these are points to consider, the study population was small and subject to effects of confounders such as non-compliance. Further large scale studies are needed to confirm these findings.[61] Moreover, dose-adjustment studies in the future may enable individualisation of DOAC therapy for better outcomes, particularly for those patients whose drug levels fall outside the desired range.

Current guidelines do not mandate regular monitoring of NOAC levels due to their wide therapeutic range and predictable PK[62]. That said, the measure of anticoagulant effect may still be useful in certain situations where treatment decisions can be influenced (e.g. in determining whether an urgent procedure can be performed safely) or in the identification of treatment adherence or overdose[63]. Although NOACs affect PT, INR and aPTT to varying degrees, these changes do not accurately correlate to their anticoagulant activity,[64] only providing qualitative evidence for the anticoagulant activity. Even then, the effects are inconsistent with the sensitivity of PT particularly poor for apixaban, while aPTT which can only be used in the qualitative assessment of dabigatran is also inconsistent in its sensitivity[65]. Hence, these coagulation assays cannot be used as accurate measures[66,67].

At present, anti-FXa assays are the only widely available specialised coagulation assay that allows a quantitative assessment of the FXa inhibiting NOACs (apixaban, rivaroxaban and edoxaban). This is reliable as plasma concentrations of NOACs closely correspond to their anticoagulant activity[68]. Anti FIIa assays (including ecarin-based anti FIIa assays) and the HEMOCLOT assay where the diluted thrombin time (TT= time taken for the formation of a stable clot) is measured in a 1:16 dilution of patient plasma compared with normal pooled
plasma, and calibrated; can be used as quantitative measures of dabigatran activity. Unfortunately, these are not widely available yet[65,66,69].

3.2 Dabigatran etexilate

Dabigatran is a synthetic, non-peptidic small-molecule direct thrombin inhibitor (DTI) which affects both clot-bound and free thrombin in a competitive, reversible and concentration-dependent manner[70]. It inactivates thrombin by binding to its active site and as this is a reversible interaction, a small amount of free, active thrombin is still available for control of haemostasis[71,72].

Dabigatran etexilate is a prodrug that was created owing to the low oral bioavailability of dabigatran (6-7%), due to its high polarity[73]. It is rapidly converted to its active form dabigatran, once absorbed. While it may be consumed with or without food, modification of the capsule by crushing or chewing it is discouraged as the oral bioavailability of dabigatran etexilate increases by 75% once the capsule shell is broken[74].

Absorption: in order to enhance absorption, the chemical composition of dabigatran etexilate is less basic and less hydrophilic, compared to its active form[75]. The drug formulation constitutes tartaric acid along with the active ingredient, which provides an acidic micro-environment that facilitates drug dissolution and absorption in the stomach and small intestine, regardless of the individual gastric pH[76].[77] In pharmacokinetic analyses of dabigatran etexilate in healthy males, peak plasma concentrations from the time of administration of 2 hours was observed, with steady state concentrations achieved within 72 hours with multiple dosing[73].

Distribution: Dabigatran has a volume of distribution of approximately 60-70L, indicative of moderate tissue distribution[72]. Only about 35% of the drug is bound to human plasma proteins[78]. The distribution phase is rapid, with plasma concentrations declining to <30% from peak levels, within 4-6 hours[79].

Metabolism: Once absorbed, nearly all of the dabigatran etexilate is hydrolysed to its active form. This reaction is catalysed by esterases within the enterocytes and continues along its transit to the portal vein and liver.[77,78] Dabigatran does not undergo significant oxidative metabolism reactions[78]. Up to 20% of it undergoes glucuronidation in a hepatic phase II reaction and these conjugated products have similar properties to and are as pharmacologically active as unconjugated dabigatran[78].

Excretion: While the 20% of the dabigatran that undergoes hepatic biotransformation gets excreted in bile, the remaining 80% is excreted by the kidneys in an unchanged form[78]. Given that dabigatran is predominantly cleared by the kidneys, dose adjustments are
required in patients with renal impairment to prevent its accumulation of drug levels within the plasma once creatinine clearance (CrCl) is ≤30ml/min.[55,80] Regular monitoring of renal function is therefore necessary for patients not just on dabigatran but all NOACs as deteriorations leading to changes in the estimated glomerular filtration rate (eGFR) have been associated with an increase in the risk of major bleeding.[81] The exposure of dabigatran depicted by the area under the curve (AUC) is 2.7 and 6 fold higher in those with moderate (CrCl 30-50ml/min) and severe (CrCl <30ml/min) renal impairment respectively[82].

**Interactions:** The risk of food-drug and drug-drug interactions is low with dabigatran due to the lack of involvement of cytochrome p450 and similar oxidoreductase enzymes.[72,78] However, drug interactions may occur during the absorption phase as dabigatran etexilate is a substrate for permeability glycoprotein (P-gp) transporter present in the entire intestine.[83] P-gp is involved in the active secretion of drugs specific to it from the cells, back into the intestinal lumen, resulting in reduced absorption and bioavailability.[84] Hence, co-administration with P-gp inducers and inhibitors is not recommended. In a population pharmacokinetic analysis from the RE-LY trial, proton-pump inhibitors, verapamil and amiodarone affected dabigatran bioavailability significantly but only to moderate amounts[80]. Dose adjustments are only required with concurrent administration of P-gp inhibitors such as dronedarone and ketoconazole, in the presence of moderate renal impairment while complete avoidance is recommended with severe renal impairment[85].

### 3.3 Rivaroxaban

Rivaroxaban is a selective inhibitor of factor Xa affecting both free and prothrombinase complex bound levels.[86] It also affects clot-bound factor Xa, inhibiting further generation of thrombin within the clot and thereby, the extension of the thrombus.[87] Rivaroxaban also results in prolongation of PT and aPTT, with maximum inhibition of factor Xa activity occurring within 3 hours after dosing.[87]

Rivaroxaban is available as a film-coated tablet and can be safely taken crushed or suspended in water, if within 4 hours.[88]

**Absorption:** Rivaroxaban is primarily absorbed in the stomach, in a process which is unaffected by medications that alter the gastric pH.[89] Absorption is reduced in the proximal part of the small intestine (resulting in a drop in the AUC for plasma concentration and C$_{\text{max}}$ by 29% and 56% respectively), and even further in the distal small bowel and ascending colon.[90] It has a bio-availability that is dose dependent. For low doses of rivaroxaban (10mg or below), the bio-availability is high (80-100%) regardless of whether it is taken with or without food, while this is reduced at higher doses (15mg and 20mg), particularly in fasted states due to absorption limited by the dissolution rate. Hence,
administration with food is recommended as this increases bioavailability by up to 80% due to an increased residence time within the stomach thought to enhance solubility and dissolution[75,91].

**Distribution:** The majority of rivaroxaban (92-95%) is bound to plasma proteins; predominantly albumin. Its volume of distribution is 50L, indicative of tissue distribution that is moderate. However, dose adjustments are not required in the extremes of body weight. In a phase I study involving administration of rivaroxaban to healthy individuals weighing ≤50kg, 70-80kg and >120kg, C_{max} was largely unaffected except in those weighing ≤50kg, where only a marginal increase was observed[92].

**Metabolism:** rivaroxaban is predominantly metabolised in the liver, with two-thirds of the drug undergoing oxidative degradation and hydrolysis by cytochrome 3A4 (CYP3A4) and cytochrome 2J2 (CYP2J2) enzymes as well as CYP independent pathways[55,93].

**Excretion:** About half of the drug that undergoes hepatic biotransformation is excreted by the kidneys while the other half takes the hepatobiliary route. The third which does not undergo metabolic degradation in the liver, is excreted in the urine an unchanged, active form[93].

In a study evaluating the effects of renal impairment on the PK and PD of rivaroxaban, renal clearance of rivaroxaban was reduced with the decline in renal function, resulting in increased plasma exposure and PD effects. AUC for plasma concentrations were 1.44-fold, 1.52-fold and 1.64-fold for those with mild (CrCl 50-79ml/min), moderate (30-49ml/min) and severe renal impairment (CrCl <30ml/min) respectively, when compared to those with CrCl ≥80ml/min[94].

Similarly, in another study evaluating the effects of hepatic impairment, significant increases in plasma concentrations of rivaroxaban were observed in those with moderate hepatic impairment (AUC = 2.27-fold compared to healthy subjects) resulting in significant increases in PD effects[95]. This has not been studied in patients with severe hepatic impairment. Hence, dose adjustments are required when CrCl is ≤50ml/min and in patients with hepatic impairment associated with coagulopathy. Caution is warranted in its use in those with moderate hepatic impairment that is not associated with coagulopathy[55].

**Interactions:** in addition to being a substrate of the CYP3A4 and CYP2J2 enzymes, rivaroxaban is also a substrate for the transporters P-gp and BCRP (breast cancer resistant gene protein). The latter is found abundantly within the epithelial cells of organs such as the liver, gut and kidney and can influence PK processes of the drug[96,97]. However, the clinical impact of this transporter is not known at present.

Concurrent administration of rivaroxaban with potent inhibitors of P-gp and/ or CYP3A4 such as azole-antimycotics and HIV protease inhibitors is not recommended while caution is advised with use of agents that affect P-gp and/or CYP3A4 to a lesser extent[55,98]. Care is
also warranted when used alongside potent CYP3A4 inducers which can decrease rivaroxaban exposure[55].

Antiplatelet agents such as aspirin and NSAIDs such as naproxen do not affect the PK of rivaroxaban but have been shown to independently increase the bleeding time when concurrently given.

3.4 Apixaban

Apixaban propagates its anticoagulant activity by inhibiting factor Xa in a highly selective and reversible fashion. Not only does it affect factor Xa which is free, clot-bound and found in the prothrombinase complex but its subsequent attenuating effect on thrombin generation leads to the indirect inhibition platelet aggregation induced by thrombin[99]. Hence, it can prolong prothrombin time (PT), international normalised ratio and activated partial thromboplastin time (aPTT)[86,100].

**Absorption:** Apixaban has an oral bioavailability of about 50% regardless of whether taken with or without food. It is primarily absorbed in the distal small bowel and ascending colon, while some absorption also takes place in the stomach[101]. In healthy individuals, \(C_{\text{max}}\) is achieved within 3hrs of oral administration[102].

**Distribution:** Approximately 87% of apixaban is bound to plasma proteins, namely albumin[103]. Unlike the other NOACs, apixaban has a relatively small volume of distribution of 21L, meaning distribution is limited within tissues and mainly confined to the blood[103]. In a study looking into the effects of extremes of body weight on the PK and PD of apixaban, only a modest increase in drug levels was noted with the \(C_{\text{max}}\) increasing by 27%. Dose adjustments are therefore not required based on body weight alone but may be indicated in the presence of other factors such as renal impairment which may have an additive effect on \(C_{\text{max}}\) levels[55,104].

**Metabolism:** Apixaban is largely unchanged within the plasma but a quarter of the orally administered dose undergoes metabolism in the liver and is recovered in the urine and faeces as metabolites. It undergoes O-demethylation, hydroxylation and sulfation reactions which are principally catalysed by the CYP3A4 enzymes, although there is minor involvement of cytochromes CYP1A2, 2C8, 2C9, 2C19 and 2J2[105]. O-demethyl apixaban sulfate is the significant metabolite found in the plasma[105].

**Excretion:** Of the NOACs, apixaban is least dependent on the kidneys for elimination. Renal clearance accounts for about a third (12-29%) of the absorbed dose while the remainder is removed via the faecal route either through biliary or direct intestinal excretion (55%)[105]. In a study looking into the effects of renal impairment, increases in plasma exposure of apixaban were observed as the renal function declined. The AUC for apixaban was 16%, 29%
and 38% higher in those with mild, moderate and severe renal impairment respectively, compared to those with normal renal function (24h CrCl =100ml/min). C\text{max} anti-FXa activity and INR were unaffected across all levels of renal impairment. Hence, dose adjustments are not required based on renal function alone[106].

In the case of hepatic impairment, the AUC for apixaban following a dose of 5mg of apixaban increased by 1.03-fold and 1.09-fold in patients with mild (Child-Pugh A) and moderate hepatic impairment (Child-Pugh B) respectively, when compared with normal subjects. Protein binding and therefore the fraction of free, unbound drug remained similar across the three groups. Further, the percentage change from the baseline INR was also comparable between them, although the baseline INR values were higher for those with hepatic impairment[107]. Apixaban may therefore be used with caution in those with mild to moderate hepatic impairment or in those with liver function enzymes (aspartate amino transferase and alanine aminotransferase) which are over 2-fold the upper limit of normal but is contra-indicated in those with severe liver disease or that which is associated with coagulopathy or high risk of bleeding[55].

**Interactions:** The numbers of drug-drug interactions with apixaban are low due to the low concentrations of drug required within the plasma, largely unchanged form and the various pathways of clearance[108]. However, like rivaroxaban, as it is a substrate for CYP3A4 as well as the P-gp and BRCP transporter proteins, concomitant administration with potent systemic inhibitors and inducers of these is not recommended[55]. Co-administration of apixaban and ketoconazole, a strong dual inhibitor of CYP3A4 and P-gp, led to an increase in the C\text{max} and AUC of apixaban by 62% and 99% respectively. However, this effect was less pronounced (C\text{max} of 31% and AUC of 40%) when apixaban was given together with diltiazem, which is a moderate inhibitor of CYP3A4 and P-gp[109]. In another study looking into the effects of rifampicin which is a strong inducer of CYP3A4 and P-gp, C\text{max} and AUC were significantly decreased and the mean apparent clearance of apixaban increased by 2.1-fold[110]. Although not contra-indicated, plasma concentrations of apixaban can be affected to varying degrees even when given together with less potent CYP3A4 and P-gp inhibitors/ inducers. Therefore, careful consideration is required before concurrent use of these medications[55].

### 3.5 Edoxaban

Edoxaban is the newest of the NOACs to receive approval for use. It is a selective, small molecule inhibitor of factor Xa which binds to it in a competitive and dose-dependent manner[111]. This in turn inhibits the generation of thrombin, and the subsequent processes that follow. Edoxaban affects free FXa, prothrombinase and also inhibits thrombin-induced platelet aggregation[112]. Like the other factor Xa inhibitors, edoxaban causes modest increases in INR, PT and aPTT[113].
Absorption: Edoxaban is available as a film coated tablet and may be taken with or without food[114]. It has an absolute oral bioavailability of 62%[115]. Absorption in the colon is limited and predominantly occurs in the proximal small intestine. $C_{\text{max}}$ is established rapidly within 1-2 hours of taking the medication and steady state is achieved after 72 hours[116].

Distribution: Approximately 55% of edoxaban is protein-bound in the plasma, which is lesser than the other FXa inhibitors. It is extensively distributed throughout the body with a volume of distribution of 107L[117].

Metabolism: Unchanged edoxaban is most prevalent in the plasma but a small amount is present as metabolites. The major metabolic pathway which results in 25% of the total dose undergoing hydrolysis, is catalysed by the enzyme carboxyl esterase-1 present in the cytosol and liver microsomes. This gives rise to the major metabolite of edoxaban M-4, which is active but accounts for less than 10% of the total edoxaban plasma exposure[118]. Minimal metabolism also takes place via the phase I processes of oxidation and conjugation, mediated by the CYP3A4 enzymes[119]. Edoxaban also undergoes phase 2 metabolism through glucuronidation. In total, six phase 1 metabolites and a glucuronide have been detected in human plasma. However, in the absence of severe renal impairment and CYP inducers, these do not contribute substantially to edoxaban’s anticoagulant activity[118].

Excretion: 50% of edoxaban is excreted via the kidneys in an unchanged form while biliary excretion and metabolism make up for the other half[120]. In the study by Bathala and colleagues which involved administration of radiolabelled edoxaban to six, healthy male subjects, over 97% of the administered dose was recovered on average, with 35.4% eliminated in the urine and 65.2% in faeces[118]. As renal function declines, plasma levels of edoxaban rise but only to a certain extent, as it is just one of the elimination pathways for edoxaban. In a pharmacokinetic study, the total exposure of edoxaban increased by 32%, 74% and 72% in individuals with mild (CrCl 50-80 ml/min), moderate (CrCl 30-50ml/min) and severe (CrCl <30ml/min) respectively compared to those with a renal function. There was no significant difference between moderate and severe renal insufficiency. Metabolic clearance plays a more dominant role in these patients[117].

The effects of hepatic impairment on edoxaban PK and PD have also been studied. Administration of 15mg of edoxaban to patients with mild and moderate hepatic impairment resulted in plasma exposure AUCs of 95.9% and 95.2% compared to their respective controls, indicating a minimal effect. Furthermore, PT was only slightly prolonged in these subjects compared to the healthy subjects, while aPTT profiles were similar across all groups[121]. Nonetheless, edoxaban is contra-indicated in patients with severe hepatic impairment and should be used with caution in those with moderate hepatic impairment due to the risk of coagulopathy and bleeding[122].
**Interactions:** much like the other FXa inhibitors, edoxaban is a substrate for the P-gp transporter protein and CYP3A4 enzymes. However, as the CYP3A4 enzymes only play a minor role in its clearance, plasma exposures of edoxaban are not significantly different to each other when administered with drugs that are dual inhibitors of P-gp and CYP3A4, whether the latter is mild, moderate or strong[117]. However, significant increases in total exposure are still seen due to inhibition of P-gp and dose reductions are required when edoxaban is given together with these drugs [122,123]. When administered with rifampicin, edoxaban clearance increased by 33% with a reduction in half-life by 50% while PT and aPTT did not change significantly. Concurrent use is therefore not contra-indicated but requires careful consideration[124].

In addition to this, concomitant administration with naproxen and low dose aspirin did not alter the PK of edoxaban but high dose aspirin increased edoxaban exposure by about 30%. All three, approximately doubled the bleeding time even though INR, PT and APTT were unaffected[125].

4. **Conclusion**

The pharmacokinetic profiles of the OACs vary from each other to different degrees and partly explain the differences in their characteristics and mode of action. The clinical effect of the drug is determined not just by one factor, but by a combination of them including PK/PD profiles, patient demographics such as age and gender, genetics and environmental aspects. Indeed, mechanisms which influence the metabolism and elimination pathways can solitarily compromise drug safety. Ultimately, it is not a question of which drug has the more superior pharmacological profile, but a matter of which pharmacological profile is most suited to the patient’s profile.

5. **Expert Opinion**

Although OAC agents belonging to the same class of drugs are similar in structure and function, there are major differences in their pharmacological profiles. In particular, it is the distinctions in the metabolic and elimination pathways are responsible for the heterogeneity in drug-drug and food-drug interactions which either attenuate or potentiate the anticoagulant activity.

Hence, insight to the pharmacokinetics and pharmacodynamics is necessary in order to achieve the maximal therapeutic benefit and minimise the possibility of adverse reactions. It is also of relevance so that an informed choice can be made between the drugs. That said, other processes such as factors influencing absorption of the drugs and pharmacodynamic interactions also play a role. Warfarin and VKAs, though expected to be replaced by NOACS, are likely to remain in play due to the breadth of experience with their use and because they
are the only OACs currently licensed for use in special populations such as those with mechanical prosthetic valves and rheumatic atrial fibrillation[15]. As such, the focus should not be shifted away from VKAs just yet and further research is needed to better understand its behaviour.

The use of warfarin remains problematic due to the diversity of its interactions and the multiple patient factors such as age, gender, diet and smoking status which influence its response. The inter-individual variations in the dose requirements for warfarin can be up to 10-fold[126]. Genetic polymorphisms of some of the key enzymes such as VKORC and CYP2C9 have been attributed to this, where the CYP2C9*2 and CYP2C9*3 alleles are associated with decreased enzyme activity and subsequent increased warfarin levels requiring a reduced dose, while single nucleotide polymorphisms in VKORC1 are associated with warfarin doses across the normal range[127]. It is estimated that only 60% of these differences are accounted for, meaning that factors which are yet to be discovered are silent at play[126]. In this regard, drug transporter science aiming to identify and characterise different transporter proteins as well as their interplay with the pharmacokinetics and subsequent clinical response is an emerging field[128]. Another is pharmacogenomics, with the increasing recognition that it is not just the pharmacokinetics and pharmacodynamics profile which influences the drug effect.

Since its acknowledgement, pharmacogenomics has advanced such that guidelines which incorporate pharmacogenetics algorithms considering VKORC1 and CYP2C9 genotypes now exist, in addition to the clinical factors, for warfarin dose prediction[129]. A step ahead of this is the implementation of pharmacogenomic diagnostics which involves screening for genotype variants prior to initiating anti-coagulation therapy. In a randomised controlled trial involving patients with AF and VTE by Pirmohamed and colleagues[130], warfarin was prescribed after genotyping, based on pharmaco-genetic algorithms in the treatment group, and standard dosing was utilised for the control group. Results indicated that that the time in therapeutic range (TTR) was significantly better in the genotype-guided group, compared to the control group. Results from another study by Kimmel and colleagues[131] however, showed no significant differences in the TTR between the genotype-guided and control groups.

The widespread uptake of pharmacogenomics diagnostics is yet to take place. Routine use may be implicated by factors such as cost and pharmaco-economic evaluations may be necessary prior to this. However, for a small sub-group of patients who are difficult to manage, or at risk of bleeding with labile INRs whose only choice of treatment is VKAs, genotyping may be of utmost value to help guide anti-coagulation treatment.

Less emphasis has been made on NOACs in this section, not due to a lesser importance but because their PK/PD profiles confer a lesser degree of interactions. Indeed, they too have
some important interactions and certain variations in their PK/PD processes are likely to be due to genetic polymorphisms, some which are known about (e.g. CYP2C9) and some which are yet to be discovered. The exact pathophysiology of reported adverse effects such as GI haemorrhage also requires further study, while breakthroughs are being made in certain avenues such as the development of potential antidotes.[132–134]

Lastly, a key area of NOAC-based research should focus on patients with chronic and end stage kidney disease; a prevalent and complex population. The complication rates in terms of major bleeding and ICH as well as the challenges in maintaining INR within the desired range with VKAs in this group of patients have resulted in a ‘now more than ever’ need for alternative drug agents such as DOACs. Unfortunately, all DOAC RCTs excluded patients with CrCl <25-30 ml/min precluding their use in these patients.[51–54]Despite this, DOAC usage has been extended beyond the RCT criteria in certain countries on the basis of limited pharmacokinetic data. This includes the lower dose of dabigatran in patients with renal impairment (CrCl 15-30ml/min) and the use of apixaban in renal patients requiring dialysis in the United States, following approval from the Food and Drug Administration.[135,136]

The discrepancies in the international guidelines concerning renal dysfunction reflect our incomplete knowledge of the pharmacology of NOACs in this group of patients and therefore warrant caution, especially as data on the long-term effects is scarce. While data from post-approval studies have been informative and a RCT comparing apixaban to phenprocoumon in patients undergoing chronic haemodialysis is underway, further studies are needed to shed light on the matter [137–139].

**Funding**

This paper was not funded.

**Declaration of Interest**

G Lip is a consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo, and a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

**Reviewer Disclosures**

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
List of figures

Figure 1 – An overview of the clotting cascade and the OAC targets within the cascade

Figure 2 – A diagrammatic representation of the vitamin K cycle and the mechanism of action of VKAs

List of Tables

Table 1 – Summary of pharmacokinetic characteristics of VKAs [23,24,33–37,25–32], [32,40–44], [15,46–50]

Table 2 – Summary of pharmacokinetic characteristics of NOACs [55,72,81,82,73–80], [55,87,96,97,88–95], [55,100,109,110,101–108], [111,112,121–125,113–120]

Table 3 – Results of safety outcomes for bleeding in NOAC phase III trials [51,52,54,140–142]

Table 4 – Summary of interactions of warfarin with drugs and food [38,143–145]
Contact Activation (Intrinsic) Pathway

Tissue Factor (Extrinsic) Pathway

Anticoagulant Proteins C, S, Z

VIIa

Tissue factor

IIa

VII

VIIIa

Rivaroxaban
Apixaban
Edoxaban

Prothrombin (II)

Thrombin (IIa)

Fibrinogen

Fibrin monomers

Fibrin polymers

XIIIa

Dabigatran

Figure 1
Figure 2

Vitamin K dependent coagulation factor

Carboxylated Vitamin K dependent coagulation factor

Vit KH₂ = Vitamin KH₂, Vit KO = Vitamin K epoxide, Vit K₁ = Vitamin K₁, VKOR = Vitamin K epoxide reductase, VKR = Vitamin K reductase
Table 1

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Enantiomers</td>
<td>R-warfarin</td>
<td>R-Phenprocoumon</td>
<td>R-Acenocoumarol</td>
</tr>
<tr>
<td></td>
<td>S-warfarin</td>
<td>S-Phenprocoumon</td>
<td>S-Acenocoumarol</td>
</tr>
<tr>
<td>Maintenance dose (mg/day)</td>
<td>2-15</td>
<td>0.75–9</td>
<td>2-10</td>
</tr>
<tr>
<td>Route of administration</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td>Target</td>
<td>Vitamin K epoxide reductase</td>
<td>Vitamin K epoxide reductase</td>
<td>Vitamin K epoxide reductase</td>
</tr>
<tr>
<td>Mechanism of action</td>
<td>Inhibits vitamin K recycling affecting vitamin K dependent clotting factors (II, VII, IX and X)</td>
<td>Inhibits vitamin K recycling affecting vitamin K dependent clotting factors (II, VII, IX and X)</td>
<td>Inhibits vitamin K recycling affecting vitamin K dependent clotting factors (II, VII, IX and X)</td>
</tr>
<tr>
<td>Reversibility</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Pro-drug</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Significant food effect on absorption</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Bioavailability</td>
<td>100%</td>
<td>100%</td>
<td>96%</td>
</tr>
<tr>
<td>Plasma concentration (µmol/L)</td>
<td>1.5–8</td>
<td>1.5–15</td>
<td>0.03–0.3</td>
</tr>
<tr>
<td>Protein binding</td>
<td>&gt;99%</td>
<td>&gt;99%</td>
<td>&gt;98%</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.08–0.12</td>
<td>0.11–0.14</td>
<td>0.22–0.52</td>
</tr>
<tr>
<td>Plasma clearance (L/h)</td>
<td>S-Warfarin – 0.10–1.0</td>
<td>S-Phenprocoumon – 0.045 – 0.055</td>
<td>S-Acenocoumarol – 28.5</td>
</tr>
<tr>
<td></td>
<td>R-Warfarin – 0.07–0.35</td>
<td>R-Phenprocoumon – 0.055–0.08</td>
<td>R-Acenocoumarol – 1.9</td>
</tr>
<tr>
<td>Elimination half-life (hours)</td>
<td>S-Warfarin – 24–33</td>
<td>S-Phenprocoumon – 110–130</td>
<td>S-Acenocoumarol – 1.8</td>
</tr>
<tr>
<td></td>
<td>R-warfarin – 35–58</td>
<td>R-Phenprocoumon – 110-125</td>
<td>R-Acenocoumarol – 6.6</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic</td>
<td>Hepatic</td>
<td>Hepatic</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Metabolic enzymes involved</th>
<th>S-Warfarin - CYP2C9 (major) R-Warfarin - CYP1A2 and CYP3A4 (major) Other: 2C19, 2C8, 2C18 and 1A2 (minor)</th>
<th>S-Phenprocoumon – CYP2C8, CYP2C9 and CYP3A4 R-Phenprocoumon – CYPC29 and CYP3A4</th>
<th>S-Acenocoumarol – CYP2C9 R-Acenocoumarol – CYP2C9, CYP1A2 and CYP2C19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elimination</td>
<td>Urine (80%) Faeces (20%)</td>
<td>Urine (65%) Faeces (35%)</td>
<td>Urine (65%) Faeces (35%)</td>
</tr>
<tr>
<td>Routine monitoring</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Interactions with food</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple</td>
</tr>
<tr>
<td>Drug-drug interactions</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple</td>
</tr>
<tr>
<td>Adverse effects (non-bleeding)</td>
<td>Hypersensitivity reactions (urticaria, anaphylaxis), calciphylaxis, tissue necrosis, systemic atheroemboli, cholesterol microemboli, limb ischaemia, gangrene, acute kidney injury, gastro-intestinal disorders such as nausea, vomiting and abdominal discomfort.</td>
<td>Rare – hepatitis, skin and tissue necrosis[146]</td>
<td>Rare – nausea, vomiting and alopecia, skin necrosis, liver injury, vasculitis</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>-------------------------------</td>
<td>---------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Route of administration</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td>Target</td>
<td>Thrombin</td>
<td>Factor Xa</td>
<td>Factor Xa</td>
</tr>
<tr>
<td>Mechanism of action</td>
<td>Inhibition of thrombin activity and generation of thrombin (TF-induced and endogenous)</td>
<td>Factor Xa inhibitor (affects, free, clot-bound and prothrombinase complex associated FXa)</td>
<td>Factor Xa inhibitor (affects, free, clot-bound and prothrombinase complex associated FXa)</td>
</tr>
<tr>
<td>Reversible interaction</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Pro-drug</td>
<td>Dabigatran etexilate</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Significant food effect</td>
<td>No</td>
<td>Yes (reduced absorption in fasted state when dose ≥10mg)</td>
<td>No</td>
</tr>
<tr>
<td>Site of absorption</td>
<td>Stomach and small intestine</td>
<td>Stomach</td>
<td>Distal small intestine and ascending colon</td>
</tr>
<tr>
<td>Bioavailability</td>
<td>6.5%</td>
<td>80-100%</td>
<td>50%</td>
</tr>
<tr>
<td>Peak plasma concentration from time of administration</td>
<td>2 hours (1.5-3h in healthy volunteers)</td>
<td>2-4 hours</td>
<td>1.5-3.3 hours</td>
</tr>
<tr>
<td>Protein binding</td>
<td>35%</td>
<td>92-95%</td>
<td>87%</td>
</tr>
<tr>
<td>Volume of distribution</td>
<td>60-70 L</td>
<td>50 L</td>
<td>21 L</td>
</tr>
<tr>
<td>Time to steady state concentrations</td>
<td>48-72 hours</td>
<td>≤96 hours</td>
<td>72 hours</td>
</tr>
<tr>
<td>Elimination half life</td>
<td>12-17 hours</td>
<td>5-9 hours (healthy)</td>
<td>8-15 hours</td>
</tr>
<tr>
<td>Hepatic metabolism</td>
<td>20% (conjugation only)</td>
<td>67%</td>
<td>25%</td>
</tr>
<tr>
<td>Metabolic enzymes involved</td>
<td>None</td>
<td>CYP3A4 and CYP 2J2 (major) CYP-independent mechanisms</td>
<td>CYP3A4 (major) CYP1A2, 2C8, 2C9, 2C19 and 2J2 (minor)</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------</td>
<td>------------------------------------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>Excretion (as a % of total dose)</td>
<td>Renal (80%)- unchanged form Biliary (20%)</td>
<td>Renal (67%) – 33% in unchanged form Hepatobiliary (33%)</td>
<td>Renal (27-30%) Hepatobiliary (70%) – direct intestinal (major) and biliary (minor)</td>
</tr>
<tr>
<td>Routine monitoring</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Interactions with food</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Drug-drug interactions</td>
<td>Few P-gp inducers (e.g. rifampicin) P-gp inhibitors in the presence of moderate-severe renal impairment</td>
<td>Combined P-gp and strong inhibitors of CYP3A4 (e.g. ketoconazole, ritonavir) Combined P-gp and strong inducers of CYP3A4 (e.g. rifampicin)</td>
<td>Combined P-gp and strong inhibitors of CYP3A4 (e.g. ketoconazole, ritonavir) Combined P-gp and strong inducers of CYP3A4 (e.g. rifampicin)</td>
</tr>
<tr>
<td>Dose adjustment with hepatic impairment</td>
<td>Avoid if risk of coagulopathy</td>
<td>No but caution with use if moderate impairment Avoid if risk of coagulopathy</td>
<td>No but caution with use if moderate impairment Avoid if risk of coagulopathy</td>
</tr>
<tr>
<td>Dose adjustment with renal impairment</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes (if present with weight ≤50kg and/or age ≥80 years)</td>
</tr>
<tr>
<td>Adverse effects (non-bleeding)</td>
<td>Gastritis like symptoms (15%), Dyspepsia</td>
<td>Rash (≥1%)</td>
<td>Skin rash (&lt;1%)</td>
</tr>
<tr>
<td>Reversal Agent</td>
<td>Idarucizumab</td>
<td>Andexanet Alfa</td>
<td>Andexanet Alfa</td>
</tr>
</tbody>
</table>

NR = Not reported
Table 3

<table>
<thead>
<tr>
<th>Trial</th>
<th>RE-LY[51]</th>
<th>ROCKET AF[52]</th>
<th>ARISTOTLE [53]</th>
<th>ENGAGE AF-TIMI 48[54]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparators</td>
<td>Dabigatran vs. warfarin</td>
<td>Rivaroxaban vs. warfarin</td>
<td>Apixaban vs. warfarin</td>
<td>Edoxaban vs. warfarin</td>
</tr>
<tr>
<td>Time in the therapeutic range for warfarin</td>
<td>64%</td>
<td>55%</td>
<td>62.20%</td>
<td>68.40%</td>
</tr>
<tr>
<td>Subgroup Event rate ,%/year (HR, 95%CI, P value)*</td>
<td>Dabigatran 150mg</td>
<td>Dabigatran 110mg</td>
<td>Rivaroxaban 20mg</td>
<td>Apixaban 5mg</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>3.11 (0.93; 0.81-1.07)</td>
<td>2.71 (0.80; 0.69-0.93)</td>
<td>3.60 (1.04, 0.90-1.20; P=0.58)</td>
<td>2.13 (0.69; 0.60-0.80)</td>
</tr>
<tr>
<td>Intracranial haemorrhage</td>
<td>0.30 (0.40; 0.27-0.60)</td>
<td>0.23 (0.31; 0.20 – 0.47)</td>
<td>0.50 (0.67; 0.47-0.93)</td>
<td>0.33 (0.42; 0.30-0.58)</td>
</tr>
<tr>
<td>Gastrointestinal haemorrhage</td>
<td>1.51 (1.50;1.19 – 1.89)</td>
<td>1.12 (1.10; 0.86-1.41)</td>
<td>3.2 (1.42; 1.22-1.66)**</td>
<td>0.76 (0.89; 0.70-1.15)</td>
</tr>
<tr>
<td>All-cause death</td>
<td>3.64 (0.88; 0.77 – 1.00)</td>
<td>3.75 (0.91; 0.80 – 1.03)</td>
<td>1.9 (0.85; 0.70 – 1.02)</td>
<td>3.94 (0.89; 0.80 – 0.998)</td>
</tr>
</tbody>
</table>

*The HRs for safety outcomes presented for RE-LY and ARISTOTLE trials are following intention-to-treat analyses, while HRs for ROCKET-AF and ENGAGE-TIMI-AF trials are following per-protocol per-treatment and modified intention-to-treat analyses respectively.

**Major or NMCR GI bleeds

**Table 4**

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Example</th>
<th>Mechanism of interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiviral drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiviral drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efavirenz</td>
<td>Moderate inhibition of CYP2C19 and of CYP3A4</td>
<td></td>
</tr>
<tr>
<td>Nevirapine</td>
<td>Strong inhibition of CYP3A4</td>
<td></td>
</tr>
<tr>
<td>Ritonavir</td>
<td>Strong inhibition of CYP3A4, inhibition of P-gp</td>
<td></td>
</tr>
<tr>
<td>Saquinavir</td>
<td>Inhibition of CYP3A4</td>
<td></td>
</tr>
<tr>
<td>Antifungal drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antifungal drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itraconazole, Ketoconazole</td>
<td>Strong inhibition of CYP3A4 and P-gp</td>
<td></td>
</tr>
<tr>
<td>Voriconazole</td>
<td>Strong inhibition of CYP3A4, CYP1A2, CYP2C9, P-gp</td>
<td></td>
</tr>
<tr>
<td>Fluconazole</td>
<td>Moderate inhibition of CYP3A4, CYP1A2, CYP2C9</td>
<td></td>
</tr>
<tr>
<td>Miconazole gel, Miconazole vaginal suppositories</td>
<td>Inhibition of CYP1A2, CYP2C9</td>
<td></td>
</tr>
<tr>
<td>Antibiotics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibiotics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amoxicillin, clavulanic acid</td>
<td>Reduction of intrinsic vitamin K synthesis</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Strong inhibition of CYP1A2</td>
<td></td>
</tr>
<tr>
<td>Levofoxacin</td>
<td>Inhibition of CYP1A2</td>
<td></td>
</tr>
<tr>
<td>Macrolides E.g. Azithromycin, Clarithromycin, Erithromycin</td>
<td>Moderate inhibition of CYP3A4 and P-gp</td>
<td></td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Inhibition of CYP1A2 and CYP2C9</td>
<td></td>
</tr>
<tr>
<td>Nafcillin</td>
<td>Strong inhibition of CYP3A4</td>
<td></td>
</tr>
<tr>
<td>Nalidixic acid</td>
<td>Inhibition of CYP1A2</td>
<td></td>
</tr>
</tbody>
</table>
Norfloxacin | Inhibition of CYP3A4  
Isoniazid | Inhibition of CYP2C9  
Chloramphenicol | Inhibition of CYP450  
Rifampicin | Induction of CYP3A4, CYP2C9 and p-gp  
Tetracyclines | Inhibition of CYP3A4  
Trimethoprim | Inhibition of CYP3A4  

**Anti-arrhythmic drugs**  
Amiodarone | Moderate inhibition of CYP3A4, CYP1A2, CYP2C9  
Dronedarone | Moderate inhibition of CYP3A4, inhibitor of P-gp  
Disopyramide | Inhibition of CYP3A4  
Propranolol | Inhibition of CYP1A2  
Propafenone | Inhibition of CYP3A4  
Quinidine | Inhibition of CYP3A4  

**Other cardiac drugs**  
Diltiazem | Inhibition of CYP3A4  
Statins (E.g. atorvastatin, lovastatin, rosuvastatin, simvastatin) | Inhibition of CYP3A4  
Telmisartan | Inhibition of CYP3A4  
Verapamil | Weak inhibition of CYP3A4; inhibition of P-gp  

**Anti-epileptic drugs**  
Barbiturates (e.g. phenobarbital) | Induction of CYP3A44, CYP2J and P-gp  
Carbamazepine | Induction of CYP3A44, CYP2J and P-gp  
Phenytoin | Induction of CYP3A44, CYP2J and P-gp  

**Other drugs**  
Fibrates (E.g. clofibrate, fenofibrate) | Inhibition of CYP3A4  
Glucagon | Inhibition of CYP3A4  
Proton pump inhibitors (e.g.) | Inhibition of CYP2C9 and increased warfarin absorption  

**Food**  
**Examples** | **Mechanism of interaction**  
Bishop’s weed, Carum Ajowan, Citrus aurantium (orange), Uncaria (Cat’s claw), Dehydroepiandrosterone, Echinacea, Goldenseal, Hydrastis Canadensis, Liquorice, Lime, Valerian, | Inhibition of CYP3A4
<table>
<thead>
<tr>
<th>Plant/Mixture</th>
<th>Effect on CYP and P-gp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild cherry</td>
<td>Inhibition of CYP1A2, CYP2C9, CYP3A4</td>
</tr>
<tr>
<td>Chamomile</td>
<td>Inhibition of CYP3A4 and CYP2C9</td>
</tr>
<tr>
<td>Cranberry, Milk thistle</td>
<td>Inhibition of CYP3A4 and CYP2C9</td>
</tr>
<tr>
<td>Devil’s claw, Garlic, Ginsenoside Rd (found in Ginseng)</td>
<td>Inhibition of CYP2C9, CYP2C19, CYP3A4</td>
</tr>
<tr>
<td>Eucalyptus, Feverfew, Fo-Ti, Peppermint, Red clover</td>
<td>Inhibition of CYP1A2, CYP2C9, CYP2C19, CYP3A4</td>
</tr>
<tr>
<td>Gingko, Lycium (Chinese Wolfberry)</td>
<td>Inhibition of CYP2C9</td>
</tr>
<tr>
<td>Grapefruit juice, Silybum marianum, Resveratrol</td>
<td>Inhibition of CYP1A2 and CYP3A4</td>
</tr>
<tr>
<td>Mango</td>
<td>Inhibition of CYP2C19</td>
</tr>
<tr>
<td>Diindolylmethane, Grapes (Vitis Vinifera), Indole-3-carbinol</td>
<td>Induction of CYP1A2</td>
</tr>
<tr>
<td>Ginsenoside Re and Rf (found in Ginseng)</td>
<td>Induction of CYP3A4 and CYP2C9</td>
</tr>
<tr>
<td>Guggul</td>
<td>Induction of CYP3A4</td>
</tr>
<tr>
<td>Limonene</td>
<td>Induction of CYP2C9</td>
</tr>
<tr>
<td>St. John’s Wort</td>
<td>Induction of CYP1A2, CYP2C9, CYP3A4 and P-gp</td>
</tr>
</tbody>
</table>
References


7. Marder VJ. Hemostasis and thrombosis: basic principles and clinical practice. [Internet]. Wolters Kluwer/Lippincott Williams & Wilkins Health; 2012. 1566 p.


60. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The Effect of


73. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics,

74. Ingelheim B. Relative bioavailability of dabigatran after administration of different application forms of a single oral dose of 150mg of dabigatran etixilate [Internet].


136. Bristol-Myers Squibb. Eliquis (apixaban) 2.5 and 5 mg Tablets. [Internet]. 2014.


